RYBREVANT® + LAZCLUZE™ achieve multitargeted inhibition of EGFR and MET, with the addition of CNS penetration1-3

  • RYBREVANT® is the first and only approved EGFR-MET bispecific antibody with immune cell–directing activity1,4
  • LAZCLUZE™ is a third-generation TKI that is a suitable combination partner for RYBREVANT® because of its high selectivity for mutant EGFR, low selectivity for wild-type EGFR, and because it is CNS–penetrant2,3

RYBREVANT® + LAZCLUZE™

RYBREVANT® (amivantamab) mechanism of action for RYBREVANT® and LAZCLUZE™RYBREVANT® (amivantamab) mechanism of action for RYBREVANT® and LAZCLUZE™

*Trogocytosis is a process in which one cell, in this case a macrophage, physically extracts and ingests cellular material of another cell.5
†ADCC involves the release of cytotoxic granules that cause tumor cell death.4,6

RYBREVANT® + LAZCLUZE™ is a chemo-free combination that provides complementary extra- and intracellular antitumor activity and CNS penetration1-4

ADCC, antibody-dependent cellular cytotoxicity; CNS, central nervous system; EGFR, epidermal growth factor receptor; MET, mesenchymal-epithelial transition; TKI, tyrosine kinase inhibitor.

RYBREVANT® + Chemotherapy

RYBREVANT® (amivantamab) mechanism of action for RYBREVANT® and chemotherapyRYBREVANT® (amivantamab) mechanism of action for RYBREVANT® and chemotherapy

*Trogocytosis is a process in which one cell, in this case a macrophage, physically extracts and ingests cellular material of another cell.5
†ADCC involves the release of cytotoxic granules that cause tumor cell death.4,6

1L, first-line.

References:

1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

2. LAZCLUZE™ [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

3. Yun J, Hong MH, Kim SY, et al. YH25448, an irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non–small cell lung cancer. Clin Cancer Res. 2019;25(8):2575-2587.

4. Cho BC, Simi A, Sabari J, et al. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89-97.

5. Bettadapur A, Miller HW, Ralston KS. Biting off what can be chewed: trogocytosis in health, infection, and disease. Infect Immun. 2020;88(7):e00930-19.

6. Grugan KD, Dorn K, Jarantow SW, et al. Fc-mediated activity of EGFR x c-MET bispecific antibody JNJ-61186372 enhanced killing in lung cancer cells. MAbs. 2017;9(1):114-126.

7. Schaer DA, Geeganage S, Amaladas N, et al. The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy. Clin Cancer Res. 2019;25(23):7175-7188.

8. Schoch S, Gajewski S, Rothfuß J, Hartwig A, Köberle J. Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics. Int J Mol Sci. 2020;21(18):6928.